New drug combo aims to stop liver cancer recurrence after surgery
NCT ID NCT05367687
First seen Nov 17, 2025 · Last updated Jun 13, 2026 · Updated 22 times
Summary
This study tested whether adding rivoceranib to camrelizumab after surgery or ablation helps prevent liver cancer from returning in patients at high risk. About 251 participants received either the combination or camrelizumab alone. The main goal was to see how long patients stayed cancer-free. This is a disease control study, not a cure, as ongoing monitoring and potential further treatment are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.